首頁 > 市場調查報告書 > 製藥

再生醫學

市場調查報告書

商品編碼

2046767

轉化再生醫學市場：全球產業規模、市場佔有率、趨勢、機會和預測（按產品類型、應用和地區分類）、競爭格局（2021-2031 年）

Translational Regenerative Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Application, By Region & Competition, 2021-2031F

出版日期: 2026年05月25日 | 出版商:

TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球轉化再生醫學市場預計將從 2025 年的 43.4 億美元大幅成長至 2031 年的 79.3 億美元，複合年成長率為 10.57%。

這個交叉學科領域利用幹細胞研究、基因治療和組織工程的最新進展，開發能夠修復、替換或再生受損人體組織和器官的臨床治療方法。推動該市場成長的關鍵因素包括全球慢性病和遺傳疾病發病率的上升，以及高齡化社會對再生療法日益成長的需求。此外，對臨床研究的大量投入以及對新型遞送系統的檢驗，正在加速這些治療方法從實驗室向患者照護的轉化，使得在2025年之前的一年中，細胞和基因療法已獲得九項監管部門的核准，取得了顯著成就。

市場概覽
預測期	2027-2031
市場規模：2025年	43.4億美元
市場規模：2031年	79.3億美元
複合年成長率：2026-2031年	10.57%
成長最快的細分市場	基因治療產品
最大的市場	北美洲

儘管前景可期，但市場擴張的主要障礙在於這些複雜治療方法的生產和治療成本高。複雜的生產要求和嚴格的品管標準需要大量的資本投入，這往往導致治療費用飆升，難以與現有的報銷模式相協調。因此，保險覆蓋範圍和支付管道的限制仍然限制著患者對這些療法的接受度，對轉化再生醫學產品的全球商業性化規模化構成了重大挑戰。

市場促進因素

幹細胞療法和基因療法的快速技術進步是轉化再生醫學市場的關鍵驅動力，顯著擴大了可治療疾病的範圍。基因編輯領域的CRISPR-Cas9等創新技術以及先進病毒載體的開發提高了這些治療方法的精準性和安全性，使研發人員不僅能夠治療罕見遺傳疾病，還能治療複雜疾病。這項技術的成熟體現在常見疾病（尤其是腫瘤學領域）臨床試驗管線的擴展。根據再生醫學聯盟統計，截至2025年1月，已有超過650項特異性針對固體癌的臨床試驗正在進行中，顯示細胞療法的應用範圍正在擴大。

公共和私人對再生醫學研發領域投資的大幅成長進一步加速了市場成長。這些投資為維持高昂的臨床試驗和擴大生產能力提供了必要的資金。這種強勁的財政支持正在穩定該行業，並幫助生物技術公司順利完成從科學發現到商業性化應用的艱難轉型。例如，整個產業在2024年上半年資金籌措了109億美元，這顯示投資者對這些治療方法的持續信心。此外，這些資金流入通常會促成高價值的策略合作，一個典型的例子是Astra Zeneca在2024年以24億美元收購Fusion Pharmaceuticals，以整合其新的再生醫學資產。

市場挑戰

轉化再生醫學療法的生產和治療成本高昂，是限制全球轉化再生醫學市場成長的主要障礙。這些治療方法需要高度複雜且資本密集的生產流程和專門的治療機制，導致最終治療價格在現有的醫療報銷框架下難以負擔。因此，第三方支付機構和國家醫療體系往往不願提供全額報銷或設置嚴格的資格要求，從而造成瓶頸，阻礙了核准的治療方法惠及更多患者並產生穩定的收入。

這種經濟差距嚴重阻礙了該行業的商業性擴充性，市場價值集中在少數克服了准入難題的「重磅」療法上，而許多其他臨床有效的療法卻難以獲得廣泛應用。近期產業數據也印證了這種有限的商業性成功，預測到2025年，全球整體細胞和基因治療領域75%的收入將來自不到10種產品。這凸顯了大多數市場新進業者在克服成本和報銷障礙以實現廣泛市場滲透方面面臨的巨大挑戰。

市場趨勢

將人工智慧 (AI) 應用於藥物發現和流程最佳化，正從根本上改變全球轉化再生醫學市場，顯著加速了有前景的生物靶點的識別，並最佳化了治療方法的設計。與傳統的研發流程相比，AI 驅動的模型能夠模擬複雜的分子間相互作用，並高精度地預測臨床療效，從而大幅縮短新型再生藥物從最初概念到臨床試驗所需的時間。這種模式轉移正吸引著大量資本投資湧入那些擅長利用機器學習設計蛋白質和抗體以應對以往難以治療的疾病的公司。 Xaira Therapeutics 的推出就是一個典型的例子，該公司已投入超過 10 億美元，用於建立一個針對困難藥物標靶的生成式 AI 平台。

同時，自動化和封閉式系統生產流程的日益普及正成為克服細胞療法生產固有的可擴展性和成本挑戰的關鍵趨勢。製造商正逐步從人工開放式加工技術轉向全自動「智慧工廠」模式，以確保產品的一致性、降低污染風險並降低單劑生產成本。再生醫學的產業化進程正促使大型製藥企業在專業生產平台上確保產能，以支持大規模商業化。例如，百時美施貴寶公司與Cellares公司簽訂了一份價值高達3.8億美元的契約，以確保其自動化Cell Shuttle平台的產能。

The Global Translational Regenerative Medicine Market is projected to expand significantly, rising from USD 4.34 billion in 2025 to USD 7.93 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 10.57%. This interdisciplinary field applies advancements in stem cell research, gene therapy, and tissue engineering to create clinical treatments that can repair, replace, or regenerate damaged human tissues and organs. Key factors driving this market's growth include the rising global incidence of chronic diseases and genetic disorders, alongside an aging population in need of restorative therapies. Furthermore, substantial investments in clinical research and the validation of new delivery systems have accelerated the translation of these therapies from labs to patient care, with the sector achieving a notable milestone of nine regulatory approvals for cell and gene therapies in the year prior to 2025.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 4.34 Billion
Market Size 2031	USD 7.93 Billion
CAGR 2026-2031	10.57%
Fastest Growing Segment	Gene Therapy Product
Largest Market	North America

Despite this promising outlook, a primary obstacle hindering market expansion is the exorbitant cost associated with manufacturing and administering these intricate treatments. The complex production requirements and rigorous quality control standards demand high capital investment, which often translates into elevated treatment prices that struggle to integrate with existing reimbursement models. Consequently, restricted insurance coverage and challenges in payment accessibility continue to limit patient adoption and pose a significant challenge to the global commercial scalability of translational regenerative medicine products.

Market Driver

Rapid technological advancements in both stem cell and gene therapies are a pivotal force propelling the translational regenerative medicine market forward, significantly broadening the spectrum of treatable conditions. Innovations such as CRISPR-Cas9 in gene editing and the development of advanced viral vectors have enhanced the precision and safety of these treatments, enabling developers to address complex illnesses beyond just rare genetic disorders. This technological maturation is evident in the expanding clinical pipeline for widespread diseases, particularly within oncology, where cell therapies are being adapted for broader applications, as highlighted by over 650 active clinical trials specifically targeting solid tumors by January 2025, according to the Alliance for Regenerative Medicine.

The market's growth is further accelerated by a substantial surge in public and private investment into regenerative medicine research and development, which provides essential capital to sustain costly clinical trials and expand manufacturing capabilities. This robust financial support has stabilized the sector, helping biotechnology firms navigate the challenging transition from scientific discovery to commercial viability. For instance, the industry successfully raised $10.9 billion in the first half of 2024, signaling sustained investor confidence in these therapeutic modalities, and this capital inflow frequently leads to high-value strategic partnerships, exemplified by AstraZeneca's $2.4 billion acquisition of Fusion Pharmaceuticals in 2024 to integrate novel regenerative assets.

Market Challenge

The prohibitive costs associated with both the manufacturing and administration of translational regenerative medicine therapies represent a formidable barrier, significantly impeding the growth of the Global Translational Regenerative Medicine Market. These treatments demand highly intricate, capital-intensive production processes and specialized delivery mechanisms, which escalate the final price of therapy to levels frequently incompatible with existing healthcare reimbursement frameworks. Consequently, third-party payers and national health systems often show reluctance to provide full coverage or impose stringent eligibility restrictions, thereby creating a bottleneck that prevents approved therapies from reaching a wider patient population and generating consistent revenue.

This financial disparity severely hinders the commercial scalability of the sector, causing market value to become heavily concentrated around a limited number of "blockbuster" treatments that have successfully navigated access challenges, while many other clinically viable options struggle to gain widespread adoption. This trend of restricted commercial success is supported by recent industry data indicating that, in 2025, 75% of the global revenue within the cell and gene therapy sector was generated by fewer than ten products, underscoring the profound difficulty most market entrants face in overcoming cost and reimbursement hurdles to achieve broad market penetration.

Market Trends

The integration of Artificial Intelligence (AI) into drug discovery and process optimization is fundamentally transforming the Global Translational Regenerative Medicine Market by significantly accelerating the identification of viable biological targets and refining therapeutic design. In contrast to conventional development pathways, AI-driven models possess the capability to simulate complex molecular interactions and predict clinical efficacy with high precision, thereby substantially decreasing the time required to advance novel regenerative therapies from initial concept to clinical trial. This paradigm shift is attracting massive capital investments into entities proficient in leveraging machine learning for protein and antibody design to tackle previously intractable conditions, exemplified by Xaira Therapeutics' launch with over $1 billion in committed capital to build a generative AI platform for challenging drug targets.

Concurrently, the increasing adoption of automated and closed-system manufacturing workflows is emerging as a crucial trend to overcome the inherent scalability and cost challenges associated with cell therapy production. Manufacturers are progressively transitioning from manual, open-processing techniques to fully automated "smart factory" models that guarantee consistency, mitigate contamination risks, and reduce the per-dose production costs. This industrialization of regenerative medicine is prompting major pharmaceutical companies to secure capacity within specialized manufacturing platforms to support large-scale commercialization, as demonstrated by Bristol Myers Squibb's deal valued at up to $380 million to reserve capacity on Cellares' automated Cell Shuttle platform.

Key Market Players

Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Johnson & Johnson Services, Inc.
GE Healthcare
Vericel Corporation
Mesoblast Limited
Pluristem Therapeutics Inc.
Lonza Group AG
Organovo Holdings, Inc.

Report Scope

In this report, the Global Translational Regenerative Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Translational Regenerative Medicine Market, By Product Type

Cell Based Product
Gene Therapy Product
Tissue Engineered Product

Translational Regenerative Medicine Market, By Application

Cardiovascular
Dermatology
Diabetes
Neurology
Oncology
Orthopedic

Translational Regenerative Medicine Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Translational Regenerative Medicine Market.

Available Customizations:

Global Translational Regenerative Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Translational Regenerative Medicine Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product Type (Cell Based Product, Gene Therapy Product, Tissue Engineered Product)
- 5.2.2. By Application (Cardiovascular, Dermatology, Diabetes, Neurology, Oncology, Orthopedic)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
5.3. Market Map

6. North America Translational Regenerative Medicine Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product Type
- 6.2.2. By Application
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Translational Regenerative Medicine Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product Type
    - 6.3.1.2.2. By Application
- 6.3.2. Canada Translational Regenerative Medicine Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product Type
    - 6.3.2.2.2. By Application
- 6.3.3. Mexico Translational Regenerative Medicine Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product Type
    - 6.3.3.2.2. By Application

7. Europe Translational Regenerative Medicine Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product Type
- 7.2.2. By Application
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Translational Regenerative Medicine Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product Type
    - 7.3.1.2.2. By Application
- 7.3.2. France Translational Regenerative Medicine Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product Type
    - 7.3.2.2.2. By Application
- 7.3.3. United Kingdom Translational Regenerative Medicine Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product Type
    - 7.3.3.2.2. By Application
- 7.3.4. Italy Translational Regenerative Medicine Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product Type
    - 7.3.4.2.2. By Application
- 7.3.5. Spain Translational Regenerative Medicine Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product Type
    - 7.3.5.2.2. By Application

8. Asia Pacific Translational Regenerative Medicine Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product Type
- 8.2.2. By Application
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Translational Regenerative Medicine Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product Type
    - 8.3.1.2.2. By Application
- 8.3.2. India Translational Regenerative Medicine Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product Type
    - 8.3.2.2.2. By Application
- 8.3.3. Japan Translational Regenerative Medicine Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product Type
    - 8.3.3.2.2. By Application
- 8.3.4. South Korea Translational Regenerative Medicine Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product Type
    - 8.3.4.2.2. By Application
- 8.3.5. Australia Translational Regenerative Medicine Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product Type
    - 8.3.5.2.2. By Application

9. Middle East & Africa Translational Regenerative Medicine Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product Type
- 9.2.2. By Application
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Translational Regenerative Medicine Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product Type
    - 9.3.1.2.2. By Application
- 9.3.2. UAE Translational Regenerative Medicine Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product Type
    - 9.3.2.2.2. By Application
- 9.3.3. South Africa Translational Regenerative Medicine Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product Type
    - 9.3.3.2.2. By Application

10. South America Translational Regenerative Medicine Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product Type
- 10.2.2. By Application
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Translational Regenerative Medicine Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product Type
    - 10.3.1.2.2. By Application
- 10.3.2. Colombia Translational Regenerative Medicine Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product Type
    - 10.3.2.2.2. By Application
- 10.3.3. Argentina Translational Regenerative Medicine Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product Type
    - 10.3.3.2.2. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Translational Regenerative Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Thermo Fisher Scientific Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. F. Hoffmann-La Roche Ltd.
15.3. Novartis AG
15.4. Johnson & Johnson Services, Inc.
15.5. GE Healthcare
15.6. Vericel Corporation
15.7. Mesoblast Limited
15.8. Pluristem Therapeutics Inc.
15.9. Lonza Group AG
15.10. Organovo Holdings, Inc.